Crescendo Biologics appoints Matthew Roe CBO
This article was originally published in Scrip
Crescendo Biologics, a company developing antibody therapies, has appointed Matthew Roe chief business officer. Mr Roe most recently served as senior director of business development and licensing for Genzyme, where he was employed for 23 years from the firm's start-up.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.